Drugs / Sandostatin LAR
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | SANDOSTATIN LAR | — | 2006-05-10 – 2008-03-03 | fda.gov ↗ |
| Approved | US (FDA) | SANDOSTATIN LAR | — | 1998-11-25 | fda.gov ↗ |
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 45 trials | ||||||
| Phase 4 | NCT01618513 | Jun 2012 → Jan 2017 | acromegaly | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT01278342 | Sep 2006 → Nov 2009 | acromegaly | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00076362 | Mar 2004 → Jul 2005 | obesity disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00068029 | Oct 2003 → May 2006 | acromegaly | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00068042 | Apr 2003 → May 2006 | acromegaly | Pfizer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05364944 Background | May 2022 → Oct 2024 | acromegaly, digestive system neuroendocrine neoplasm | Debiopharm International SA | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sandostatin LAR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01278342 ↗ |
| Route | Intramuscular | “40 mg intramuscular (i.m.) every 28 days for 3 months” NCT01278342 ↗ |